CSPC Pharmaceutical (HKG:1093) unit CSPC Innovation submitted another listing application to the Hong Kong Stock Exchange for the proposed listing of its Hong Kong-listed shares after its previous application lapsed, according to a Thursday bourse filing.
It is expected that CSPC Innovation will remain an indirect subsidiary of the pharma company after the listing.
Details of the listing, such as the timetable, size, and structure of the offering, are yet to be finalized.
The listing is subject to the relevant regulatory approvals.